Thomas Henkel

Title: Thomas Henkel: Innovator in Gene Transcription Research

Introduction

Thomas Henkel is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of gene transcription, holding a total of 2 patents. His work focuses on developing methods and compositions that aid in the diagnosis and treatment of diseases associated with gene expression.

Latest Patents

Henkel's latest patents include a process for inhibiting the transcription of genes and an Epstein-Barr virus transcription factor binding assay. The invention provides methods for identifying pharmacological agents that can selectively modulate gene expression. The methods involve combining CBF1, the Epstein-Barr virus transcription factor EBNA2, and a candidate pharmacological agent. This mixture is incubated under specific conditions to determine if the candidate agent can inhibit the binding of CBF1 to EBNA2. The methods are particularly suited for high-throughput screening, utilizing advanced robotic systems for efficiency.

Career Highlights

Throughout his career, Thomas Henkel has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable organizations include Tularik Limited and Boehringer Ingelheim International GmbH. His experience in these companies has contributed to his expertise in gene transcription research and innovation.

Collaborations

Henkel has collaborated with several professionals in his field, including Michael Gregory Peterson and Patrick Baeuerle. These collaborations have further enhanced his research and development efforts in gene transcription.

Conclusion

Thomas Henkel is a distinguished inventor whose work in gene transcription has the potential to impact medical diagnostics and treatments significantly. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge and improving healthcare outcomes.